UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)													
1. Name and Address of Reporting Person * Dal Poggetto John			2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]					5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD			3. Date of Earliest Transaction (Month/Day/Year) 04/23/2020						X Officer (give title below) Other (specify below) Chief Financial Officer				
(Street) PETALUMA, CA 94954			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Ta	ıble I - Nor	ı-Deri	vative S	ecurities	Acquii	red, Dispo	osed of, or l	Beneficially (Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	f Code (Instr. 8)		n 4. Securities Acquire		uired of (D)	ed 5. Amount of Securities D) Beneficially Owned Followin Reported Transaction(s)		es Following	6. Ownership Form:	7. Nature of Indirect Beneficial
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 a	nstr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	
Common Stock, \$0.0 value	0001 par	04/23/2020		A		3,086	A	(1)	3,201			D	
			Derivative Securiti	ies Acquire	ed, Dis	sposed o	f, or Bend	eficiall	-		aror nambo	·	
Derivative Security (Instr. 3) Conversion or Exercise (Instr. 3)	3. Transaction	Table II - I (a 3A. Deemed Execution Date ear)	Derivative Securities, puts, calls, wa 4. Transaction Code Year) (Instr. 8)	ies Acquire arrants, op	Perso conta the fo ed, Dis tions, 6. Da and E	ons who ained in orm dis	o responding this formula of the securitisable on the securitisable of the securities o	eficially ities) 7. Tit Amo Unde Secure	not required valid y Owned tle and unt of earlying rities		9. Number of Derivative Securities Beneficially	of 10. Ownersk Form of Derivativ	ve Ownershi
Derivative Security				Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			(Instr 4)	r. 3 and		Owned Following Reported Transaction(s (Instr. 4)	Security Direct (I or Indire (s) (I) (Instr. 4))	
			Code V	(A) (D)	Date Exerc		Expiration Date	Title	Amount or Number of Shares				
Reporting Ov	vners												
				Relat	ionshi	ips							
Reporting Ow	mer Name / A	ddress	4007										

		Relationships					
Reporting Owner Name / Address		Director	Director Owner Officer		Other		
1129 N. N	etto John OMA PHARMACEUTICALS, INC. ICDOWELL BLVD MA, CA 94954			Chief Financial Officer			

Signatures

/s/ John Dal Poggetto	04/24/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares were granted pursuant to the mutual separation and release agreement dated April 14, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.